COMPLETE RESPONSE UNDER SORAFENIB TREATMENT FOR HEPATOCELLULAR CARCINOMA IS ASSOCIATED TO DEVELOPMENT OF DERMATOLOGY ADVERSE EVENTS

被引：0
|
作者：
Diaz-Gonzalez, A. [1 ]
Rimola, J. [2 ]
Maria, R. [1 ]
Darnell, A. [2 ]
Varela, M. [3 ]
Pons, F. [4 ]
Hernandez-Guerra, M. [5 ]
Delgado, M. [6 ]
Castroagudin, J. F. [7 ]
Matilla, A. [8 ]
Sangro, B. [9 ]
de Lope, C. R. [10 ]
Margarita, S. [11 ]
Gonzalez, C. [12 ]
Huertas, C. [13 ]
Minguez, B. [14 ]
Ayuso, C. [2 ]
Bruix, J. [1 ]
机构：
[1] Hosp Clin Barcelona, Liver Unit, BCLC GRP, Barcelona, Spain
[2] Hosp Clin Barcelona, Dept Radiol, BCLC Grp, Barcelona, Spain
[3] Hosp Univ Cent Asturias, Liver Unit, Oviedo, Spain
[4] Hosp Univ Puerta de Hierro, Digest Dis Dept, Madrid, Spain
[5] Hosp Univ Islas Canarias, Liver Unit, Tenerife, Spain
[6] Hosp Univ La Coruna, Digest Dis Dept, La Coruna, Spain
[7] Hosp Clin Univ Santiago, Digest Dis Dept, Santiago De Compostela, Spain
[8] Hosp Gen Univ Gregorio Maranon, Digest Dis Dept, Madrid, Spain
[9] Clin Univ Navarra, Liver Unit, Dept Internal Med, Pamplona, Spain
[10] Hosp Univ Marques de Valdecilla, IDIVAL, Liver Unit, Digest Dis Dept, Santander, Spain
[11] Germans Trias & Pujol, Digest Dis Dept, Liver Unit, Badalona, Spain
[12] Hosp Gen Univ Valencia, Liver Unit, Digest Dis Dept, Valencia, Spain
[13] Hosp Univ Doctor Josep Trueta, Digest Dis Dept, Girona, Spain
[14] Hosp Univ Vall dHebron, VHIR, Dept Internal Med, Liver Unit, Barcelona, Spain
来源：
JOURNAL OF HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
10.1016/S0168-8278(16)00433-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-038
引用
收藏
页码：S319 / S319
页数：1
相关论文
共 50 条
  • [1] Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events
    Rimola, Jordi
    Diaz-Gonzalez, Alvaro
    Darnell, Anna
    Varela, Maria
    Pons, Fernando
    Hernandez-Guerra, Manuel
    Delgado, Manuel
    Castroagudin, Javier
    Matilla, Ana
    Sangro, Bruno
    Rodriguez de Lope, Carlos
    Sala, Margarita
    Gonzalez, Carmen
    Huertas, Carlos
    Minguez, Beatriz
    Ayuso, Carmen
    Bruix, Jordi
    Reig, Maria
    HEPATOLOGY, 2018, 67 (02) : 612 - 622
  • [2] Adverse events of sorafenib in hepatocellular carcinoma treatment
    Pang, Yongsheng
    Eresen, Aydin
    Zhang, Zigeng
    Hou, Qiaoming
    Wang, Yining
    Yaghmai, Vahid
    Zhang, Zhuoli
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (06): : 2770 - 2782
  • [3] SORAFENIB TOLERANCE AND ADVERSE EVENTS IN THE FIRST LINE TREATMENT OF HEPATOCELLULAR CARCINOMA
    Herren, C.
    Beyrer, J. K.
    Chen, L.
    Li, L.
    Heaton, P. C.
    Bowman, L.
    Girvan, A.
    VALUE IN HEALTH, 2017, 20 (05) : A87 - A87
  • [4] Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma
    Huan, Hong-Bo
    Lau, Wan-Yee
    Xia, Feng
    Ma, Kuan-Sheng
    Bie, Ping
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (39) : 14505 - 14509
  • [5] Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma
    Hong-bo Huan
    Wan-Yee Lau
    Feng Xia
    Kuan-sheng Ma
    Ping bie
    World Journal of Gastroenterology, 2014, (39) : 14505 - 14509
  • [6] Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US
    Sugimoto, Katsutoshi
    Moriyasu, Fuminori
    Saito, Kazuhiro
    Rognin, Nicolas
    Kamiyama, Naohisa
    Furuichi, Yoshihiro
    Imai, Yasuharu
    LIVER INTERNATIONAL, 2013, 33 (04) : 605 - 615
  • [7] SIGNIFICANCE AND MANAGEMENT OF ADVERSE EVENTS ASSOCIATED WITH SYSTEMIC THERAPY WITH SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Hilgard, Philip
    Ertle, Judith M.
    Penndorf, Volker
    Haag, Sebastian
    Gerken, Guido
    HEPATOLOGY, 2008, 48 (04) : 962A - 962A
  • [8] Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma
    Yao, Xuesong
    Yan, Dong
    Liu, Dezhong
    Zeng, Huiying
    Li, Huai
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (04) : 929 - 935
  • [9] Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
    Soria, Anna
    Calvo, Mariona
    Casas, Meritxell
    Vidales, Zara
    Munoz-Martinez, Sergio
    Sapena, Victor
    Puigvehi, Marc
    Canillas, Lidia
    Guardeno, Raquel
    Gallego, Adolfo
    Minguez, Beatriz
    Horta, Diana
    Clos, Ariadna
    Montoliu, Silvia
    Roget, Merce
    Reig, Maria
    Vergara, Mercedes
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib
    Granito, Alessandro
    Marinelli, Sara
    Negrini, Giulia
    Menetti, Saverio
    Benevento, Francesca
    Bolondi, Luigi
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (02): : 240 - 249
12345